Your browser doesn't support javascript.
loading
Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial.
Cunningham, David; Stenning, Sally P; Smyth, Elizabeth C; Okines, Alicia F; Allum, William H; Rowley, Sam; Stevenson, Laura; Grabsch, Heike I; Alderson, Derek; Crosby, Thomas; Griffin, S Michael; Mansoor, Wasat; Coxon, Fareeda Y; Falk, Stephen J; Darby, Suzanne; Sumpter, Kate A; Blazeby, Jane M; Langley, Ruth E.
Afiliação
  • Cunningham D; Department of Oncology, Royal Marsden NHS Foundation Trust, London, UK. Electronic address: david.cunningham@rmh.nhs.uk.
  • Stenning SP; Medical Research Council Clinical Trials Unit, University College London, London, UK.
  • Smyth EC; Department of Oncology, Royal Marsden NHS Foundation Trust, London, UK.
  • Okines AF; Department of Oncology, Royal Marsden NHS Foundation Trust, London, UK.
  • Allum WH; Department of Oncology, Royal Marsden NHS Foundation Trust, London, UK; Department of Surgery, Royal Marsden NHS Foundation Trust, London, UK.
  • Rowley S; Medical Research Council Clinical Trials Unit, University College London, London, UK.
  • Stevenson L; Medical Research Council Clinical Trials Unit, University College London, London, UK.
  • Grabsch HI; Section of Pathology and Tumour Biology, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK; Department of Pathology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, Netherlands.
  • Alderson D; Department of Surgery, Queen Elizabeth Hospital, Birmingham, UK.
  • Crosby T; Department of Clinical Oncology, Velindre Hospital, Cardiff, UK.
  • Griffin SM; Northern Oesophagogastric Cancer Unit, Royal Victoria Infirmary, Newcastle-upon-Tyne, UK.
  • Mansoor W; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.
  • Coxon FY; Department of Oncology, Newcastle Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, UK.
  • Falk SJ; Department of Oncology, Bristol Haematology and Oncology Centre, Bristol, UK.
  • Darby S; Department of Clinical Oncology, Weston Park Hospital, Sheffield, UK.
  • Sumpter KA; Department of Oncology, Freeman Hospital, Newcastle-upon-Tyne, UK.
  • Blazeby JM; Centre for Surgical Research, School of Social and Community Medicine, University of Bristol, Bristol, UK.
  • Langley RE; Medical Research Council Clinical Trials Unit, University College London, London, UK.
Lancet Oncol ; 18(3): 357-370, 2017 03.
Article em En | MEDLINE | ID: mdl-28163000
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Neoplasias Esofágicas / Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Junção Esofagogástrica Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Neoplasias Esofágicas / Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Junção Esofagogástrica Idioma: En Ano de publicação: 2017 Tipo de documento: Article